ERBB2 and breast carcinoma: For instance, in human epidermal growth factor receptor 2 (HER2)-positive early-stage breast cancer, emerging evidence suggests that anthracycline-free regimens may offer similar efficacy while minimizing cardiotoxic risk [4].